R R

What Is a Complement Inhibitor?

A complement inhibitor is a medicine that reduces activity within the complement system, a group of immune proteins involved in inflammation and destruction of targeted cells. Excessive or misdirected complement activation contributes to several rare blood, kidney, neurological, and autoimmune disorders. Complement inhibitors target specific proteins or steps within the classical, lectin, alternative, or terminal pathways. Examples include eculizumab, ravulizumab, sutimlimab, pegcetacoplan, iptacopan, danicopan, crovalimab, and zilucoplan.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is a Complement Inhibitor?

A complement inhibitor is a medicine that reduces activity within the complement system, a group of immune proteins involved in inflammation and destruction of targeted cells. Excessive or misdirected complement activation contributes to several rare blood, kidney, neurological, and autoimmune disorders. Complement inhibitors target specific proteins or steps within the classical, lectin, alternative, or terminal pathways. Examples include eculizumab, ravulizumab, sutimlimab, pegcetacoplan, iptacopan, danicopan, crovalimab, and zilucoplan.

read more about complement inhibitor ...

Copy this HTML:

Copy HTML Copied!

What Are Complement Inhibitors Used For?

Complement inhibitors are used for selected complement-mediated disorders. Depending on the drug, indications can include paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, cold agglutinin disease, and other specialized conditions. The target and approved disease differ among products. Treatment commonly requires confirmation of the diagnosis and ongoing assessment by a specialist.

How Do Complement Inhibitors Work?

Some medicines block complement component 5 or its cleavage and prevent formation of the terminal membrane attack complex. Others inhibit upstream components such as C1s, C3, factor B, factor D, or other pathway proteins. The result can reduce complement-mediated red-cell destruction, inflammation, tissue injury, or abnormal immune attack. Blocking different points in the cascade produces different clinical effects and infection risks.

How Are Complement Inhibitors Given?

Complement inhibitors are available as intravenous infusions, subcutaneous injections, and selected oral products. Dosing schedules range from daily oral treatment to injections or infusions separated by weeks. Vaccination, laboratory testing, infection-risk review, and disease-specific baseline assessments are commonly required before treatment. Some products are available only through a Risk Evaluation and Mitigation Strategy or another controlled safety program.

What Are the Side Effects and Infection Risks?

Complement inhibition can increase susceptibility to serious infections, particularly from Neisseria meningitidis and other encapsulated bacteria, depending on the target. Life-threatening meningococcal infection can occur even after recommended vaccination. Other risks include infusion or injection reactions, headache, respiratory infections, blood-cell changes, and return or worsening of the underlying disease after discontinuation. Fever, severe headache, stiff neck, rash, confusion, or rapidly worsening illness requires immediate medical evaluation.

Frequently Asked Questions About Complement Inhibitors

Why do complement inhibitors increase meningococcal risk?

Terminal complement activity is important for defense against Neisseria meningitidis. Blocking this pathway can leave patients vulnerable even when vaccination produces antibodies.

Are all complement inhibitors monoclonal antibodies?

No. The group includes monoclonal antibodies, peptides, small molecules, and other therapeutic formats. Products also target different points in the complement cascade.

Does vaccination remove the infection risk?

No. Recommended vaccination reduces risk but does not eliminate it. Patients must still recognize symptoms and seek immediate evaluation when meningococcal infection is suspected.

Can a complement inhibitor be stopped suddenly?

Stopping can allow complement activity and the underlying disease to return, sometimes with serious complications. Discontinuation requires a condition-specific monitoring and transition plan.

References

SOLIRIS (Eculizumab Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722. Date Accessed August 6, 2026.

ULTOMIRIS (Ravulizumab-cwvz Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a590d9-0217-43c7-908d-e62a71279791. Date Accessed August 6, 2026.

EMPAVELI (Pegcetacoplan Injection): Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215014s011lbl.pdf. Date Accessed August 6, 2026.

FABHALTA (Iptacopan Capsules): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a76b5845-6e21-4d3b-ad07-cd8df1b60bee. Date Accessed August 6, 2026.

ENJAYMO (Sutimlimab-jome Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=281cf1d4-6296-4416-858e-9bff46d01b71. Date Accessed August 6, 2026.